Oryzon gets EMA approval to start phase II Hope-2 vafidemstat study for PMS treatment
The study is for Phelan–McDermid syndrome treatment. Reuters source text says the approval is to initiate the Hope-2 phase II study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.